ImetelChat

Current cash on balance sheet is a lot higher than the guesses / estimates made on this board in the past weeks. Exercise of warrants has bolstered.

I doubt there are many who are excited at this point. More like road weary, but, alive. My guess is the conference call will be better than a swift kick in the teeth, but i suppose that is a pretty low bar :lol: Wish this was something I could be excited about. After last years double mallet over th...

Earnings call - 9AM EST
Abstracts released online - 9AM EST

IMO, These experts are coming because they expect to ale a lot of money on these shares (and enjoy their job, etc etc)… but I assume the shares are a top reason to leave a kush job at bigger, more stable to say the least, companies. Who came from Incyte? Did you post that yet? And do you know (yet) ...

They keep coming. The only thing that is safe to say about Geron is that they continue to offer up tons of shares and experts keep on joining the company. Not much is certain in these uncertain times, so I’ll just say : If they are not a legitimate company with a legitimate product, they sure are do...

I suppose MAIA not to mention, once the drug is approved… as a first in class drug with a unique MOA, there will likely be a swell of testing other methods of telomerase inhibition.

Geron hiring a Senior Director of Intellectual Property, as of today - guess they finally decided to start defending their IP.

Rotten carrot. HA! That’s as good any an analogy I suppose. Well rotting vegetation does make for top line mulch, so I guess it’s still not beyond reason to say a partner will emerge, all puns intended. Still optimistic despite all else. That optimism is based on (hyper) focus on the data, about 10 ...

Indeed. The drug will be approved. And re:FDA article, they get it wrong sometimes for sure, in both directions. Still the gold standard, the rigidity and focus on scientific methodology ensures it. Still humans involved along the way which ensures fallacy. But Imetelstat will get approved. The four...

My guess is the Institutional ownership will be 80% before the stock makes a move up. Rangebound from $1.90-$2.30 or so until then. Interesting new topics about the FDA, EMA, Thio drug still in early stage trials, etc… no comments on all of that info as I am just waiting for approvals at this point....

New CFO Robertson is clearly a heavy hitter in the oncology space. Note the role at Momenta, acquired by JNJ for a cool $6.5B. Ms. Robertson brings to Geron over 30 years of financial and commercial operations experience. Prior to joining, she served as the Chief Financial Officer and Treasurer of E...

Don’t think I saw this interview from Dr. Zeidan (Yale) posted. If so, it’s a semi-oldie (June ‘23) but definitely a goodie: https://medicine.yale.edu/news-article/promising-phase-iii-results-give-hope-to-people-living-with-myelodysplastic-syndromes/ Edit: Yep, I see it was posted in June when publi...

The IMpress trial with clinical sites online and dosing patients for several months would merit a poster, to convey the trial design for this critical trial in the industry. I think tangentially todays release and quote from Dr. Feller shows that the company is working to get more light on the thera...

Thanks,
You don’t think IMpress trial will be mature enough for data?

https://www.targetedonc.com/view/follow ... r-risk-mds

Recent Updates in the Management of Lower-Risk Myelodysplastic Syndrome : Episode 5
Follow-Up Efficacy Data of Imetelstat in Lower-Risk MDS
Eytan M. Stein, MD

(Keeps the confidence of success high as we wait)

FYI for this October event, doubtful we’ll have the ability to view, or receive any video, transcript or notes for the meeting. Adding to the discussion of Dr. Lane returning a decade later. Stating the obvious, the initiation of the trial in Aussie is a great sign and a clear indication to Dr. Lane...

Just the facts. I won’t sell and I would assume institutions will be buying/selling, but net buying. I, like I am sure most of not all are, are spent. I’ll let the experts do their thing, and get across the finish line. Which is coming no doubt. So it is time for a vacation from these boards. This i...

It's, obviously, not just this decision in a vacuum. It's the body of work: Let's not even take hESC technology, disappearing into oblivion. It's the liver safety hold in 2013. It's JNJ, successful P2 trial... compassionate use, then out the door. It's the MDS trial being pushed back again and again...

Well, 10 months away.

The irony is, it will be approved. Still infuriating.

HA